Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sandoz Group Ltd ( (CH:SDZ) ).
Sandoz reported strong sales growth for the first nine months of 2025, with net sales reaching USD 8,057 million, a 5% increase at constant currencies. The company’s biosimilars segment showed significant growth, representing over 30% of net sales for the first time. Sandoz also upgraded its full-year margin guidance, reflecting the successful execution of its strategic roadmap and the expansion of its biosimilar infrastructure. The company is well-positioned for future growth, with anticipated biosimilar launches and a focus on sustainable European supply amidst geopolitical challenges.
The most recent analyst rating on (CH:SDZ) stock is a Hold with a CHF49.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group Ltd is a global leader in the pharmaceutical industry, specializing in affordable medicines. The company focuses on the production and distribution of generics and biosimilars, with a significant market presence in Europe, North America, and internationally.
Average Trading Volume: 764,882
Technical Sentiment Signal: Buy
Current Market Cap: CHF22.3B
See more data about SDZ stock on TipRanks’ Stock Analysis page.